NasdaqHealth CarePharmaceutical PreparationsPHILADELPHIA, PA

Context Therapeutics Inc. CNTX

Ask your AI

Estimated market cap $16.61M91.88M shares, shares as of Nov 6, 2026CIK 1842952

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

22.7% of shares · 20 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Context Therapeutics Inc.'s latest quarterly report, compared with the one before.

Filed Nov 10, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Context Therapeutics Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jun 9, 2025. Insiders have two business days to file.

Recent insider trades

Martin A. Lehr Chief Executive Officer, Director	Jun 9, 2025 Form 4 ↗	Buy	+$70.0K 100,000 sh @ $0.70	-100.1%
Alex C. Levit Chief Legal Officer, Corp. Sec	Jun 6, 2025 Form 4 ↗	Buy	+$11.6K 20,000 sh @ $0.58	-98.7%
Jennifer Lynn Minai-Azary Chief Financial Officer	Jun 6, 2025 Form 4 ↗	Buy	+$25.6K 40,010 sh @ $0.64	-98.7%

All CNTX insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

20.86M shares

51 funds report CNTX. Values checked against market prices.

Funds own 68% of shares (Q2 2026)

79 funds hold the stock.

Q3 2026: 23% · 5,560 of ~8,900 funds reported so far

Q2 202576%
Q3 202575%
Q4 202571%
Q1 202686%
Q2 202668%
Q3 2026 (so far)23%

Q3 2026. 15 new, 20 added to, 11 trimmed, 43 exited since Q2 2026.

Top 13F holders
#
1	BlackRock, Inc. 13F ↗	6.14M	$1.8M	-0.5%
2	Vanguard Capital Management LLC 13F ↗	3.43M	$1.0M	unchanged
3	Acadian Asset Management LLC 13F ↗	1.99M	$597.0K	+96.9%
4	Geode Capital Management, LLC 13F ↗	1.90M	$569.5K	+3.6%
5	State Street Corp 13F ↗	1.46M	$437.4K	+3.0%
6	Renaissance Technologies LLC 13F ↗	967,475	$290.6K	-7.1%
7	Russell Investments Group, Ltd. 13F ↗	671,074	$201.6K	+8907.7%
8	Vanguard Portfolio Management LLC 13F ↗	634,673	$190.4K	-0.7%
9	UBS Group AG 13F ↗	524,545	$157.4K	+1761.2%
10	Vanguard Fiduciary Trust Co 13F ↗	428,125	$128.4K	-1.3%

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds CNTX, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Context Therapeutics Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Context Therapeutics Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q4 2021	19	—	3.55M	$9.4M
Q1 2022	16	-3	2.90M	$6.3M
Q2 2022	20	+4	3.64M	$6.3M
Q3 2022	24	+4	4.13M	$4.6M
Q4 2022	24	0	3.88M	$2.5M
Q1 2023	22	-2	1.29M	$722.6K
Q2 2023	22	0	2.24M	$3.6M
Q3 2023	23	+1	2.58M	$3.9M
Q4 2023	24	+1	3.56M	$4.0M
Q1 2024	25	+1	3.94M	$5.4M
Q2 2024	34	+9	58.97M	$118.2M
Q3 2024	42	+8	56.68M	$111.2M
Q4 2024	52	+10	72.80M	$76.4M
Q1 2025	42	-10	71.41M	$43.7M
Q2 2025	39	-3	68.62M	$45.0M
Q3 2025	37	-2	68.97M	$66.8M
Q4 2025	43	+6	65.31M	$96.0M
Q1 2026	59	+16	79.17M	$206.1M
Q2 2026	79	+20	62.81M	$34.8M
Q3 2026	51	-28	20.86M	$6.3M

Each point is a quarter-end, from Q4 2021 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (21077P108). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2021) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes12 in 12 mo 8-K events1 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Context Therapeutics Inc.
Address: 2001 MARKET STREET, SUITE 3915 UNIT #15, PHILADELPHIA, PA 19103
Phone: 267-225-7416
Fiscal year ends: Dec 31
Filer category: emerging growth company
Incorporated in: DE
Listed as: CNTX (Nasdaq)
Former names: Context Therapeutics LLC (until 2021)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.1808−$0.02 (−8.69%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.1808 · High $0.275Nov 13, 2026

Aug 13, 2026Low $0.1808 · High $0.5303Nov 13, 2026

Nov 13, 2025Low $0.1808 · High $3.36Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.